NEA led a $40m Series C funding round in Affinia Therapeutics.

NEA, venture capital firm, led a $40m Series C funding round in Affinia Therapeutics, a gene therapy company, with participation from Eli Lilly & Company, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime, GV, Mass General Brigham Ventures, and Perceptive Advisors. “We are grateful to this outstanding group of institutional and strategic investors who share our excitement about our novel, cardiotropic capsids and pipeline. This financing recognizes the potential of our novel capsids and the value of our lead program AFTX-201, bringing it one step closer to potentially become the first-in-class and best-in-class genetic medicine to treat BAG3 DCM,” Rick Modi, Affinia Therapeutics CEO.